The AUA Just Updated Its BPH Guidelines for 2026: What Patients Need to Know
Published: May 2026 • Written by David Robbins, MD, Board-Certified Urologist, North Miami, FL
On May 7, 2026, the American Urological Association (AUA) released its updated guideline for the management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH)—commonly known as an enlarged prostate. This is one of the most significant updates in BPH management in years, containing 62 evidence-based recommendations that reflect new medications, new minimally invasive procedures, and a stronger emphasis on shared decision-making between doctor and patient.
BPH affects millions of American men and is one of the most common reasons for a visit to a urologist. If you are dealing with urinary symptoms like weak stream, frequent urination, nighttime waking, or incomplete emptying, these updated guidelines directly affect how your treatment should be approached.
What Is BPH?
Benign prostatic hyperplasia is the non-cancerous enlargement of the prostate gland that occurs naturally as men age. The prostate surrounds the urethra, and as it grows, it can compress the urinary channel and cause symptoms including:
- Frequent urination, especially at night (nocturia)
- Weak or intermittent urinary stream
- Difficulty starting urination (hesitancy)
- Feeling that the bladder has not fully emptied
- Urgency—the sudden, strong need to urinate
By age 60, more than 50 percent of men have some degree of BPH. By age 85, that number exceeds 90 percent. While BPH is not cancer and does not increase your cancer risk, it can significantly affect quality of life, sleep, and daily activities if left untreated.
Key Changes in the 2026 AUA BPH Guidelines
Shared Decision-Making Is Now Central
The updated guidelines place a stronger emphasis on individualized, patient-centered care. Rather than a one-size-fits-all treatment ladder, the 2026 guidelines encourage urologists to discuss all available options with patients—from medications to minimally invasive procedures to surgery—and to tailor the approach based on the patient's specific symptoms, anatomy, goals, and preferences.
Minimally Invasive Procedures Get Stronger Endorsement
The guidelines reflect the growing body of evidence supporting minimally invasive surgical therapies (MISTs) for BPH, including procedures designed to preserve sexual function while relieving urinary symptoms. Technologies like Rezum (water vapor therapy), UroLift, and Aquablation are now supported by stronger data and receive more detailed recommendations within the guidelines.
These procedures offer men an alternative to traditional TURP (transurethral resection of the prostate) with generally shorter recovery times, lower risk of sexual side effects, and the ability to be performed in outpatient settings.
Sexual Function Preservation Is a Priority
One of the most important themes in the 2026 update is the recognition that preserving sexual function—including ejaculatory function—is a legitimate and important treatment goal for many men. The guidelines now provide more detailed guidance on which procedures are more likely to preserve ejaculation versus those that may cause retrograde ejaculation, helping urologists and patients make better-informed choices.
New FDA-Cleared Devices Recognized
The guidelines acknowledge recently cleared devices including the Urocross Expander System (cleared March 2026) and the Zenflow Prostatic Spring, both of which use mechanical approaches to open the prostatic urethra without removing tissue. While longer-term data is still being collected, these devices represent a new category of treatment options for men with BPH.
What This Means for You
If you are currently managing BPH symptoms with medication and wondering whether there is a better option, or if you have been told you need surgery and want to explore less invasive alternatives, the 2026 guidelines reinforce that you have more choices than ever before. The most important step is a thorough evaluation by a board-certified urologist who can assess your prostate size, symptom severity, and treatment goals.
At Urological Consultants of Florida, Dr. Robbins offers comprehensive prostate health services including medication management, minimally invasive procedures, and surgical options for BPH. We take the time to discuss every option so you can make an informed decision.
Call (305) 575-2771 to schedule a prostate evaluation.
